Advanced Oncotherapy (AVO) secures of £24m financing for Harley Street
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support the Company’s provision of vendor financing for the […]
I’m Banging on About this Cancer-Zapper, Again – But It’s Still on Course for Share Success – Malcolm Stacey at ShareProphets
Parts 1 and 2 by Malcolm Stacey 1) Hello Share Crafters. In the past I’ve probably written too many pieces on a medical share which I like. During that period, I’ve seen the shares rise from 2p to 17p. Sadly, the share price has reversed back to 6.5p. And the worst of it is I […]
Advanced Oncotherapy (AVO) – Holdings in Company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying […]
Advanced Oncotherapy (AVO) – CEO discusses proton beam therapy
Michael Sinclair, CEO, discusses AVO’s light proton therapy system, its advantages and potential to disrupt the radiation oncology market.
Advanced Oncotherapy (AVO) wins best health care Award at UK Stock Market Awards 2016
Advanced Oncotherapy (AVO) wins best health care Award at UK Stock Market Awards 2016.
Sanjeev Pandya of Advanced Oncotherapy (AVO) interviewed by BRR Media
Sanjeev Pandya, Executive Vice President for Global Business Development for Advanced Oncotherapy (AVO) provides an update to shareholders on development progress of the Company’s novel proton accelerator. Sanjeev also introduces Michel Baelen, the recently appointed Global Head of Regulatory Affairs. Click the image to watch.
Daily Actions – UK Main & AIM markets 31032016
Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London AIM Market ST Rec. changed From To Banks & Investment Banks Arden Partners Sell Neutral Basic Resources […]
Proton beam therapy, the silver bullet for cancer? – Proactive Investors
by Josh Allsopp – Proactive Investors Radiotherapy remains the mainstay of cancer treatment, with over half of all patients undergoing radiation based treatment of some sort. There has been a great deal of coverage recently about the possibility of an ultimate cancer cure that uses the body’s own immune system to take out the killer […]
Advanced Oncotherapy (AVO) – Strategic Update from Nicolas Serandour
Advanced Oncotherapy (AVO) – COO and CFO Nicolas Serandour is interviewed by BRR Media, and provides an update on AVO’s recent activity including the agreement with Thales and the companies financial strategy. Link here to listen.
British Medical Journal – A (relatively) risky business: the link between prostatic radiotherapy and second malignancies
This article published yesterday in the British Medical Journal and showing the link between radiotherapy and secondary tumour, highlights the need for a more targeted radiotherapy – i.e. Proton Beam Therapy There is a well recognized association between exposure to radiation and carcinogenesis. The development of second malignancies after therapeutic radiation depends on the primary […]